Original filename: Kaye.pdf
This PDF 1.7 document has been generated by / Foxit PhantomPDF Printer Version 3.1.0.0815, and has been sent on pdf-archive.com on 19/03/2018 at 09:21, from IP address 213.7.x.x.
The current document download page has been viewed 253 times.
File size: 106 KB (5 pages).
Privacy: public file
Download original PDF file
Stanley B Kaye
DSc MD FRCP FRSE FMedSci
Cancer Research UK Professor of Medical Oncology
Royal Marsden Hospital
Sycamore House, Downs Road
Surrey SM2 5PT
Telephone: 020 8661 3538/9
Fax: 020 8661 3541
Stanley B Kaye BSc MD FRCP FRCR FRSE FMedSci
Date of birth
5th September 1948 (Leeds, England).
Married, 3 Children
1958 - 1965 Roundhay School, Leeds.
1966 - 1972 Charing Cross Hospital Medical School
Professor of Medical Oncology, Royal Marsden Hospital
Emeritus Professor, Institute of Cancer Research, London
Qualifications and Awards
July 1972 – March 1977
April 1977 – December 1979
January 1980 – December 1980
January 1981 – August 2000
September 2000 – July 2011
August 2011 – November 2013
December 2013 onwards
B.Sc. (Honours) in Biochemistry, 2nd Class, 2:1, University of London.
M.B., B.S. University of London.
M.D. University of London.
Fellow Royal College of Physicians (London)
Fellow Royal College of Physicians and Surgeons (Glasgow)
Fellow Royal College of Radiologists (London)
Fellow Royal College of Physicians (Edinburgh)
Fellow of Royal Society of Edinburgh
Fellow of the Academy of Medical Sciences
DSc, University of London
Junior doctor hospital posts at Charing Cross Hospital,
Hammersmith Hospital and University College Hospital London.
Senior Registrar and CRC Research Fellow
Department of Medical Oncology, Charing Cross Hospital, London.
(Professor K Bagshawe, Dr E Newlands)
Acting Staff Specialist in Medical Oncology,
Ludwig Institute for Cancer Research, Royal Prince Alfred Hospital,
Senior Lecturer, then Professor and Head of Department
Department of Medical Oncology, University of Glasgow.
Cancer Research UK Professor of Medical Oncology,
Royal Marsden Hospital and Head of Section of Medicine, Institute of
Head of Division of Clinical Studies, Institute of Cancer Research.
Professor of Medical Oncology, Royal Marsden Hospital.
Emeritus Professor, Institute of Cancer Research
Senior Fellow, Biomedical Research Centre, Royal Marsden Hospital
a) Administrative Experience
CRC/Cancer Research UK
Member of Cancer Research UK Phase I Clinical Trials Committee
Chairman of CRC Phase II Clinical Trials Committee
Vice-Chairman of CRC Scientific Committee
Chairman of CRC Clinical Trials Committee
Member of CRC Technology Scientific Advisory Board
Member of CRC Ventures Scientific Advisory Board
Chairman of Cancer Research UK Clinical Trials Committee
Member of Cancer Research UK Scientific Executive Board
2005 – present
Vice Chairman, CRUK Clinical Trials Advisory & Awards Committee
Chair of Cancer Research UK Clinical and Translational Research Committee
Member of CRUK Scientific Strategy Advisory Group
Chair: ad-hoc review of EORTC activities
Chair: West of Scotland CRUK Cancer Centre Governance Board
Member of Chemotherapy Subcommittee of Urology Group
Member of Early Clinical Trials Group
Member of Protocol Review Committee
Secretary of Scientific Audit Committee
Chairman of Scientific Audit Committee
Chairman of Early Clinical Trials Group
Elected Member of the Board of EORTC
Chairman, Fellowship and Awards Committee of European Society of Medical
Member, ESO Scientific Committee
Member of Working Party on Testicular Cancer
Member of Working Party on Bladder Cancer
Chairman of Working Party on Bladder Cancer
Member of Working Party on Osteosarcoma
Member of Cancer Therapy Committee
Member of Gynaecological Cancer Working Party
Member of Oncology Therapy Advisory Committee (OTAC)
Member of Advisory Board (previously Molecular & Cellular Medicine Board)
Member of Scottish Breast Cancer Trials Group
Member of Scottish Urology Group
Treasurer of West of Scotland Lung Cancer Group
Member of Cancer Advisory Group/Clinical Effectiveness Group,
Greater Glasgow Health Board
Secretary of West of Scotland Oncological Organisation
Chairman West of Scotland Oncological Organization
Member of Scottish Gynae Cancer Trials Group (Chairman 1986-1996)
Member of Scottish Melanoma Group
Member of Scottish Cancer Co-ordinating and Advisory Committee
Grant Holder, Scottish Cancer Therapy Network
Member of Oncology Board of Academy of Scottish Royal Colleges
Member of Gynaecological Cancer Group
Member of Main Committee
Chairman of Testicular Cancer Group
Member of National Cancer Research Network/Institute Steering Group.
Trust Board/Health Board
Non-Executive Director of West Glasgow University Hospitals NHS Trust
Non-Executive Director of North Glasgow University Hospitals NHS Trust
Chairman, Clinical Governance Committee of North Glasgow University
Hospitals NHS Trust
Chairman of Gynaecological Cancer Tumour Working Group, S.W. London
Chairman of New Drugs Group, S.W. London Cancer Network
Member of London Networks New Drugs Group
Royal Marsden Hospital
Chairman of Drugs & Therapeutics Advisory Committee.
Head of Gynaecology Unit.
Member of Medical Advisory Committee
Head of Drug Development Unit
Chair of the Genetic Modification Committee
2015 – present
Chair, Royal Marsden Clinical Trials Unit Strategy Board
Institute of Cancer Research
2001 - present
Member of Joint Research Committee (with RMH).
2001 – present
Member of Clinical Research Directorate.
Member of Corporate Management Group
Member of the Executive Strategy Board
Head, Division of Clinical Studies
ESMO Award Lecture
Bagshaw Lecture (BACR)
Michel Clavel Lecture (EORTC/NCI)
ESTRO Award Lecture (ECCO)
BACR Plennary Lecture
Lifetime Achievement Award RMH
Quality in Care NHS Lifetime Achievement Award
MD Anderson, Madrid Lifetime Foundation Award
Scientific Advisory Boards, etc.
1988/95 Advisor on Cancer Services North Wales/North Lancashire
London Implementation Group, Cancer Services Subcommittee
Member of Scientific Advisory Board, St Luke's Institute for Cancer Research, Dublin
Member of Universities Research Assessment Exercise (RAE)
Committee, (Panellist, Unit of Assessment 3), and Vice-Chairman,
Cancer Subpanel (2001)
Member of External Advisory Panel to Committee on Safety of Medicines (CSM)
1997-2000 Member of Scientific Advisory Board, Bradford War on Cancer
1997/1998 Member of ICRF Clinical Review Committee
2000-2002 Member of ICRF Scientific Advisory Board
2001-2004 Member of Prize Committee, General Motors Cancer Research Foundation. Chairman in 2003
Member of Scientific Advisory Council, Institut Curie, Paris
onwards Val d’Hebron Institute, Barcelona
National Cancer Institute, Napoli
Beatson Institute, Glasgow
Cancer Sciences Institute, Singapore
Member of Prize Committee, Szent-Gyorgyi Prize
In addition, over the past 5-10 years, I have been a member or chairman of clinical/scientific advisory boards
to a number of UK-based/international pharmaceutical companies, (including Cyclacel, BoehringerIngelheim, PharmaMar, Kudos, Astex, OSI, Roche, Merck, Johnson & Johnson, AstraZeneca, GSK & Astellas). I
have also been a member/chairman of 10 data monitoring committees for international clinical trials in
cancer. I have acted as Grant Assessor (and Member of Site Visit Committees) for Cancer Research UK, CRC,
MRC, Irish Cancer Society, ICRF, AICR, North of England CRC, Academy of Medical Sciences and others.
Over the past 5 years, I have given 35 invited lectures at various national and international meetings,
including 4 Award lectures. I have held four visiting professorships in other universities and have held
research grants totaling almost £9million. My main current research interests include drug development in
cancer, and ovarian cancer and I have published over 400 peer-reviewed papers, 105 invited reviews and
have edited 6 books*.
Having retired from the ICR in December 2013, I now have 4 new roles:
a) Professor of Medical Oncology and Senior Fellow to the Biomedical Research Centre at the Royal
Marsden Hospital – continuing to provide advice to the tumour teams on their drug development
b) Director of Research for London Cancer Alliance (LCA) – now translated to Royal Marsden and
Partners Cancer Vanguard. This is a new model of integrated cancer care and as its first Director of
Research, I have responsibility for developing its Research Strategy, with a particular focus on
improving outcomes of treatment and patient experience.
c) Visiting professor at the University of Singapore – advising on their plans for an enlarged Drug
Development Unit as well as having a role in mentoring. I also chair the New Agents in Cancer
Committee (NACC), in Singapore.
d) Visiting Professor at University of Glasgow – advising on their strategy for translational cancer
*Publication list available on request or online at www.icr.ac.uk